NCT01971476View on ClinicalTrials.gov

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 22, 2013

Primary Completion Date

June 1, 2015

Study Completion Date

January 27, 2017

Conditions
LeukemiaNeoplasms
Interventions
DRUG

volasertib

intravenous administration on day 1of a treatment course

Trial Locations (5)

9000

UNIV UZ Gent, Ghent

50937

Universitätsklinikum Köln (AöR), Cologne

75248

INS Curie, Paris

150 06

University Hospital Motol, Prague

00165

Osp. Pediatrico Bambin Gesù, Roma

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01971476 - Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known | Biotech Hunter | Biotech Hunter